DelveInsight’s, “Immune Thrombocytopenia Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune Thrombocytopenia pipeline landscape. It covers the Immune Thrombocytopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Immune Thrombocytopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Immune Thrombocytopenia Pipeline @ https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Immune Thrombocytopenia Pipeline Report
* On March 02, 20260- Eli Lilly and Company initiated a phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
* On February 27, 2026- Incyte Corporation initiated a phase 2a study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
* On February 27, 2026- Sanofi announced a study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
* On February 24, 2026- Novartis Pharmaceuticals conducted a phase III study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count greater than or equal to 30 G/L in adult participants with primary ITP.
* On February 23, 2026- Principia Biopharma, a Sanofi Company announced a Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia. This was a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count
This release was published on openPR.
